Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
For years and years, pharmaceutical pricing has been under attack by consumers, professionals, and payers. More recently, the U.S. government has dramatically stepped up its assault, with price reduction proposals from Congress and stern words from President Trump indicating that drug pricing is a major ongoing focus of the administration. The 2018 timeline was dotted with government jabs at pharma pricing, as well as some attempts to take real action.
A sales rep preparing for her week isn’t thinking, What’s in my sales dashboard? What is my progress towards my call plan? She’s thinking, What are the burning issues in my territory this week? How should I adjust my plan based on the latest events and information that I have? Then she manually navigates her way through dashboards and reports to find these answers.
The market research company Gartner predicts that consumer demand for voice devices such as Amazon Echo and Google Home will generate $3.5 billion by 2021. These intelligent voice assistants, plus other digital technologies such as the Apple Watch, are slowly but steadily being adopted in healthcare.
Ogilvy Health recently asked some of its agency leaders – in creative, payer, digital, planning, and account – to share what they’re tracking in 2019.
In the era of precision medicine, life sciences companies are transforming customer engagement with complete, accurate and up-to-date customer data.
Most pharmaceutical brands are really happy with a handful of their agencies, satisfied with some, and not too thrilled with one or two. TGaS uncovered four areas to watch in 2019 through its benchmark-based consultancy.
Med Ad News asked its sources for the Agenda 2019 special feature which key questions for 2019 we’d left out. This is what they told us.
Top 10 Pipelines To Watch: 2019 Annual Report
Analysts, Ankylosing Spondylitis (AS), Annual Reports, Antiretroviral Drugs, Atopic Dermatitis (Eczema), Autoimmune Diseases, B Cells, Big Pharma, Biologics, Biopharma, Biotechnology, Blockbusters, BRCA Gene, BRCA mutation, Breakthrough Therapy Designation, Business, Cancer, CAR-T Therapy, Cells, Chemotherapy, Clinical Data, Clinical Trials, Collaborations, Crohn's Disease, Cystic Fibrosis, Drug Discovery, EU, European Medicines Agency (EMA), Fast Track Designation, FDA, FDA/Regulatory, February 2019, Future Blockbusters, Gene Editing, Generalized Myasthenia Gravis (gMG), Genomics, HIV, Human Genome, Immune Cells, Immune System, Immune-Mediated Diseases, Immunotherapy, Inflammatory Diseases, Injectables, Innovation, Integrase strand transfer inhibitors, Issue Archives, Japan, M&A, Med Ad News, Monoclonal Antibodies, Multiple myeloma, Neoantigens, Neurology, Neuromyelitis Optica Spectrum Disorder (NMOSD), New Drug Applications, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Non-Small Cell Lung Cancer (NSCLC), Nonalcoholic Steatohepatitis (NASH), Nuclear Medicine, Oncology, Orphan Drug Designation, Paroxysmal Nocturnal Hemoglobinuria (PNH), Precision Medicine, Prescription Drug User Fee Act (PDUFA), Priority Medicines (PRIME) Designation, Priority Review Voucher, Product Pipelines, Proteins, Psoriatic Arthritis, R&D, Radioligands, Rare Disorders, Research, Rheumatoid Arthritis, RNA Interference (RNAi), Sickle Cell Disease, Small Molecules, Special Reports, T-Cells, Top 10 Pipelines, Top 10 Pipelines To Watch, Tumors, Ulcerative Colitis, Ultra Rare DiseasesThe return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
With Congressional hearings on drug prices, proposed rules for Medicare plans and new ICER efforts to link outcomes to value, finding answers on how to price and pay for drugs is still difficult.